Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins.

Date publication

mars 2021

Journal

Cardiovascular diabetology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr SCHINI-KERTH Valérie , Dr AUGER Cyril

Tous les auteurs :
Park SH, Belcastro E, Hasan H, Matsushita K, Marchandot B, Abbas M, Toti F, Auger C, Jesel L, Ohlmann P, Morel O, Schini-Kerth VB

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33726768

Résumé

Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced cardiovascular risk in type 2 diabetes patients independently of glycemic control. Although angiotensin II (Ang II) and blood-derived microparticles are major mediators of cardiovascular disease, their impact on SGLT1 and 2 expression and function in endothelial cells (ECs) and isolated arteries remains unclear.

Mots clés

Angiotensin II, Circulating microparticles, Empagliflozin, Endothelial senescence and dysfunction, SGLT1, SGLT2

Référence

Cardiovasc Diabetol. 2021 Mar 16;20(1):65